SABS — SAB Biotherapeutics Share News
0.000.00%
Last trade - 00:00- $258.40m
- $158.97m
Brief: Sab Biotherapeutics Announces First Publication Of Promising Nonclinical Data For Therapy Against Pneumonic Plague
Brief: Sab Biotherapeutics Inc Files For Mixed Shelf Of Up To $50 Million – SEC Filing
Brief: SAB Biotherapeutics Announces Progress On U.S. FDA's Phased Review Of Company's Groundbreaking DiversitAb Platform
SAB Biotherapeutics Inc expected to post a loss of 8 cents a share - Earnings Preview
Brief: SAB Biotherapeutics Inc SAB-176 And Oseltamivir Combination Therapy Shows Promising Results In Preclinical Studies
Brief: Sab Biotherapeutics - Grade 3 Or Higher Treatment Emergent Adverse Event Rates Were Similar Between Sab-185 And Regen-Cov Arms
SAB Biotherapeutics soars on FDA's 'breakthrough' tag for influenza therapy
SAB Biotherapeutics jumps on FDA's 'breakthrough' tag for influenza therapy
Brief: Sab Biotherapeutics Announces U.S. FDA Grants Breakthrough Therapy Designation To Sab-176 Influenza Immunotherapy
U.S. STOCKS ON THE MOVE-Tupperware, Netflix, Copper miners
U.S. STOCKS ON THE MOVE-Groupon, Hecla Mining, Harley-Davidson
U.S. STOCKS ON THE MOVE-Stratasys, Knightscope, Consolidated Communications
Brief: Sab Biotherapeutics Granted U.S. FDA's 'Fast Track' tag for influenza therapy
SAB Biotherapeutics jumps on FDA's 'fast track' tag for influenza therapy
Brief: SAB Biotherapeutics Inc- Cash And Cash Equivalents Were $15.0 Million As Of December 31, 2022
SAB Biotherapeutics Inc expected to post a loss of 4 cents a share - Earnings Preview
Brief: Sab Biotherapeutics Files Prospectus Related To Up To 14.7 Million Shares Of Common Stock That Selling Stockholders May Sell
Brief: Sab Biotherapeutics Inc Received Nasdaq Notice Of Delisting
Brief: SAB Biotherapeutics Receives $8.2 Million In Closeout Of DoD Contract